ArticleCanadian journal of public health = Revue canadienne de sante publique2026
Sex differences in the prevalence and cardiometabolic risk profiles of steatotic liver disease: A Canadian Longitudinal Study on Aging analysis.
Article in Canadian journal of public health = Revue canadienne de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis.Current obesity reports · 2026Pooled it
- Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Association of Systemic Inflammatory Indices with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Superior inflammatory response and MASH progression inFrontiers in immunology · 2026Article
- Call to action: integrating steatotic liver disease into public health strategies in Canada.Lancet regional health. Americas · 2025Review
- Barriers and facilitators to liver fibrosis screening: Perspectives and practices of Canadian primary care physicians.Canadian liver journal · 2025Article
- Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2025Review
- Sex Differences in MASLD After Age 50: Presentation, Diagnosis, and Clinical Implications.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveSteatotic liver disease (SLD) is absent from global public health agendas. Our study is the first to comprehensively examine SLD prevalence in Canada, focusing on sex differences.
methodsWe used data from the Canadian Longitudinal Study on Aging between 2012 and 2018. Steatosis was identified using the validated NAFLD Ridge Score. Using the most recent diagnostic criteria, we defined metabolic (dysfunction)-associated steatotic liver disease (MASLD), metabolic dysfunction-associated alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) and estimated prevalences by sociodemographic factors. Survey-weighted adjusted prevalence ratios (aPR) for MASLD (sex-stratified) and MetALD were estimated using Poisson regression with robust standard errors.
resultsA total of 24,888 people (51.4% female; median age 58 years) were included. The most common subtype of SLD was MASLD, 35% (95%CI, 34-36), followed by MetALD 2.6% (2.3-2.9), and ALD 0.8% (0.6-1.0). Overall, the prevalences for MASLD and MetALD were significantly higher among males at 46% (45-48) and 3.7% (3.2-4.2) compared to females at 24% (23-26) and 1.6% (1.2‒2.1), respectively. Lower household incomes were associated with higher MASLD prevalence in females (aPR, 2.9, 2.4-3.5) and males (aPR, 1.1, 1.0-1.3). Multimorbidity was high among the MASLD group; 31 unique MASLD phenotypes based on cardiometabolic characteristics were identified. Females with MASLD were also more likely to have more cardiometabolic conditions compared to males with MASLD.
conclusionIn this large Canadian cohort, we found significant sex differences in SLD burden and cardiometabolic features. Epidemiological assessments are necessary to improve preparedness for the significant projected increase in advanced liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.